Not Just What, But When: Neoadjuvant Pembrolizumab in Melanoma

New trial results show that pembrolizumab given both before and after surgery for stage 2B-3 melanoma improved event-free survival compared with adjuvant therapy alone.
Medscape Medical News

source https://www.medscape.com/viewarticle/980549?src=rss